Can an arthritis drug make melanoma immunotherapy safer?
NCT ID NCT05034536
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding infliximab (a drug used for arthritis) to standard immunotherapy (pembrolizumab or nivolumab+relatlimab) can prevent severe immune-related side effects in people with advanced melanoma. About 36 patients who have not had prior treatment will receive either the combination or immunotherapy alone. The goal is to see if this approach reduces side effects without compromising the cancer-fighting effect.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (Keytruda) or nivolumab+relatlimab combined with infliximab
What this could lead to
If successful, this approach could make standard melanoma immunotherapy safer by reducing severe side effects, allowing more patients to complete treatment.
What could go wrong
This is a small, early-phase trial with only 36 participants, so results may not apply broadly. Adding infliximab could also reduce the cancer-fighting effect of immunotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States